The Influence of Pyridoxine in Diabetic Peripheral Neuropathy
- Ellis R Levin,
- Thomas A Hanscom,
- Mark Fisher,
- Walter A Lauvstad,
- Alec Lui,
- Ann Ryan,
- David Glockner and
- Seymour R Levin
- Research, Ophthalmologic, Medical, Rehabilitation and Neurologic Services of the Endocrinology Section and Diabetes Research Laboratory, Wadsworth Veterans Administration Medical Center, Jules Stein Eye Institute, and UCLA School of Medicine Los Angeles, and the Division of Medicine and Biochemistry, Indiana University School of Medicine Indianapolis
- Address reprint requests to Ellis R. Levin, Endocrinology Section, Wadsworth Veterans Administration Medical Center, Jules Stein Eye Institute and UCLA School of Medicine, Wilshire and Sawtelle Boulevards, Los Angeles, California 90073.
Abstract
To determine the role of pyridoxine in the treatment of diabetic peripheral neuropathy, 18 symptomatic diabetic patients were treated with vitamin B6 or placebo in a double-blind controlled study. Only one patient had a low plasma pyridoxal phosphate level at the start of the study. After 4 mo of treatment with pyrodoxine hydrochloride (50 mg three times daily) 6 of 9 pyridoxine-treated and 4 of 9 placebotreated patients noted significant relief from their neuropathic symptoms. There was no difference between the two groups with regard to fasting plasma glucose, motor nerve conduction velocity, or ophthalmologic examination at the beginning or at the conclusion of the study. Our results suggest that vitamin B6 deficiency is not a factor in the etiology of diabetic peripheral neuropathy. Furthermore, treating diabetic peripheral neuropathy with high dose vitamin B6 or placebo results in a similar frequency of symptomatic improvement.
- Copyright © 1981 by the American Diabetes Association











